Views & Analysis Unstable and unpredictable? The reality of the PPRS Has the UK PPRS scheme met its five objectives?
Views & Analysis Just how much does the NHS spend on medicines? Confidential discounts and the PPRS pricing system are making it more difficult to arrive at an accurate figure.
Views & Analysis Three NICE thresholds for cost-effectiveness: does that make... NICE wants a new, third threshold for rare disease drugs - but what's the evidence behind it?
Views & Analysis The PPRS medicines pricing scheme: is it working for both si... The PPRS has now reached the half-way stage - a look at the stats so far.
Views & Analysis International benchmarking and NICE Is NICE willing to change, or is it inflexible? It is being pressed to compare itself to other HTA organisations.
Views & Analysis Sitting uncomfortably? The UK’s PPRS and statutory schemes Do the PPRS and the statutory scheme run effectively in parallel?
News Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.6bn-plus valuation.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
